❌

Reading view

  •  

Consensus framework for the validation of generative AI: call for collaborators on the Validation Accords

Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04647-5

Consensus framework for the validation of generative AI: call for collaborators on the Validation Accords
  •  

Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial

Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04607-z

Following preclinical development, a randomized first-in-human trial showed that treatment with an inhaled, lung-epithelium-targeted siRNA directed against the receptor for advanced glycation end-products (RAGE) was safe and well tolerated and reduced RAGE levels in serum and bronchoalveolar lavage fluid.
  •  

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

Nature Medicine, Published online: 09 September 2026; doi:10.1038/s41591-026-04615-z

In a phase 2 randomized clinical trial, treatment with the myeloperoxidase (MPO) inhibitor mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.
  •  

From algorithms to patient outcomes — lessons from one of the first randomized trials of AI in medicine

Nature Medicine, Published online: 07 September 2026; doi:10.1038/s41591-026-04633-x

The first generation of medical artificial intelligence (AI) was judged on whether algorithms could match clinicians. The next generation should be judged on whether carefully designed human–AI systems can improve patient outcomes.
  •  
❌